NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company developing targeted therapies, including antibody-drug conjugates, for cancer patients whose disease does not respond to or progresses on current therapies. Its main candidates are SIM0505, which targets CDH6, and LNCB74, which targets B7-H4; both are in Phase 1 clinical trials. NextCure licenses SIM0505 and related compounds from Simcere Zaiming, which retains rights in China, Hong Kong, Macau, and Taiwan. LNCB74 is being developed with LigaChem Biosciences under an agreement that shares development costs and commercial profits equally. NextCure is also seeking partners for its oncology programs NC410 and NC525 and its preclinical non-oncology programs NC605 and NC181. The company paused its internal manufacturing operations in March 2024 and maintains its manufacturing facility for potential future use. NextCure is headquartered in Baltimore, Maryland.
ADAR1 Capital Management, LLC purchased 12,333 indirectly-held shares of NextCure, Inc. (NXTC) at $5.10 on 2026-11-11. Filed jointly with Schneeberger Daniel (10% owner).
NextCure (NXTC) reported a Q3 GAAP EPS of -$1.29, missing estimates by $0.39. Cash reserves fell to $8.7M from $41.8M due to operational costs, partially offset by equity sales and asset sales.
NextCure, Inc. (NXTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results – Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing – S-4 Declared Effective by SEC; S
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning NXTC (NextCure, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent NXTC coverage spans corporate actions, insider activity and earnings.
In the last 30 days, NXTC insiders filed 6 SEC Form 4 transactions — 6 purchases ($140K) and no sales. The most active reporter was ADAR1 Capital Management, LLC with 6 filings.
Small insider purchase by a 10% owner may signal confidence but limited market impact.
Earnings miss likely triggers sell pressure.
The financing bolsters the merger outlook, likely driving share price upside as investors price in reduced execution risk.
The CMO departure may raise concerns about integration and execution of the merger, potentially pressuring the stock.
Executive departure may raise uncertainty about the merger and could pressure the stock.
AlphAI scores every news story that mentions NXTC with an AI model for sentiment and relevance, and aggregates insider trades from NextCure, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ADAR1 Capital Management, LLC purchased 12,333 indirectly-held shares of NextCure, Inc. (NXTC) at $5.10 on 2026-11-11. Filed jointly with Schneeberger Daniel (10% owner).
NextCure (NXTC) reported a Q3 GAAP EPS of -$1.29, missing estimates by $0.39. Cash reserves fell to $8.7M from $41.8M due to operational costs, partially offset by equity sales and asset sales.
NextCure, Inc. (NXTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results – Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing – S-4 Declared Effective by SEC; S
NextCure plans to terminate Chief Medical Officer Udayan Guha by October 31, 2026, as part of its pending merger with Avere Therapeutics. Severance terms include standard benefits and additional payments if the merger closes, as outlined in an SEC filing.
NextCure, Inc. (NXTC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 26, 2026 NextCure, Inc. (the “Company”) determined that the employment of Dr. Udayan Guha, M.D., Ph.D., Chief
ADAR1 Capital Management, LLC purchased 10,851 indirectly-held shares of NextCure, Inc. (NXTC) at an average of $4.95 ($4.83–$5.10) across 3 trades over 2026-10-23 to 2026-10-27. Filed jointly with Schneeberger Daniel (10% owner).
NextCure, Inc. (NXTC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN RE NEXTCURE, INC. ) ) ) C.A. No. 2026-____-_____ verified petition for relief pursuant to 8 del. c. § 205 Petitioner NextCure, Inc. (“NextCure” or the “Company”), by and through its undersigned co
NextCure, Inc. (NXTC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On August 28, 2026, NextCure, Inc. (the "Company") and ARE-8000/9000/10000 Virginia Manor, LLC entered into a Ninth Amendment to the parties’ lease agreement dated January 30, 2019 (the "Amendment") with respect to the Compan
Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
Simcere Zaiming, Inc. sold 30,000 indirectly-held shares of NextCure, Inc. (NXTC) at $6.16 ($0.18M total) on 2026-08-10.
